Home
Storia in 12 fonti
Nova caneta contra obesidade leva pacientes a perder até 32 kg em estudo de fase 3 | G1
Retatrutida, molécula da Eli Lilly ainda em investigação, mostrou perda média de 28,3% do peso corporal em 80 semanas; resultado se aproxima de índices observados em cirurgias bariátricas.
- ·
nbcnews.com
People lost up to 85 pounds on Lilly’s experimental weight loss drug, company says
The results — the most weight loss ever seen in a medication trial — put the drug’s effectiveness on par with bariatric surgery.
- ·
endpoints.news
Lilly’s triple agonist still leads among late-stage obesity assets
Eli Lilly said Thursday that its triple agonist retatrutide allowed obesity patients to lose about a quarter of their weight after taking the shot for 80 weeks. This is the…
